視網膜靜脈阻塞治療的全球市場規模、佔有率和成長分析：按疾病類型和治療方法- 行業預測（2024-2031）

2022年全球視網膜靜脈阻塞治療市場規模將為139.2億美元，從2023年的154.1億美元成長到2031年的347.5億美元，預計在預測期內（2024年~2031年）將成長年複合成長率為10.70%。

由於 RVO 盛行率上升以及易患該疾病的老年人口不斷增加，視網膜靜脈阻塞 (RVO) 治療市場正在經歷顯著成長。 RVO 是一種常見的視網膜血管疾病，如果不及時治療，會帶來視力喪失和失明的風險。該市場提供多種治療選擇，包括藥物、雷射治療和手術干預，旨在增加血液循環、減少黃斑部水腫和防止視力喪失。市場按治療類型、最終用戶和地區進行細分，抗 VEGF 藥物作為控制血管增生和黃斑部水腫的有前景的選擇脫穎而出。特別是在北美和歐洲，醫療基礎設施發達，新治療方法較早推出。由於醫療保健意識的提高和醫療設施的改善，亞太地區也在經歷成長。研發投資的增加、診斷技術的進步以及製藥公司和研究機構之間的合作等因素正在推動創新治療方法的創造。此外，預計市場將進一步關注個人化醫療和以患者為中心的方法。隨著對有效 RVO 治療的需求增加，製造商和醫療保健提供者正在合作提供更容易獲得和更有效的解決方案，旨在改善受這種疾病影響的人們的生活品質。Masu。

目錄

執行摘要

• 市場概況
• 命運之輪

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模估算
• 市場假設與限制

母市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務

主要市場考察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• Start-Ups分析
• 原料分析
• 創新矩陣
• 研發線產品分析
• 總體經濟指標
• 主要投資分析
• 關鍵成功因素
• 競爭程度

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 監管環境
• 波特的分析
• 對未來中斷的特殊考慮

全球視網膜靜脈阻塞治療市場：依疾病類型

• 市場概況
• 視網膜中央靜脈阻塞（CRVO）
• 視網膜分支靜脈阻塞症（BRVO）

視網膜靜脈阻塞治療的全球市場：治療方法

• 市場概況
• 抗血管內皮生長因子（抗VEGF）
• 皮質類固醇藥物
• 其他

全球視網膜靜脈阻塞治療市場規模：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2021年）
• 主要市場參與者所採取的策略
• 關鍵成功策略
• 近期市集活動
• 主要企業市場佔有率（2021年）

主要企業簡介

• Alcon
• Pfizer Inc.
• Genentech
• Regeneron Pharmaceuticals Inc.
• Allergan plc
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Sanofi
• Thrombogenics Inc.
• Acucela Inc.
• Clearside Biomedical Inc
• EyePoint Pharmaceuticals Inc.
• Sirnaomics Inc.
• Astellas Pharma Inc.
• Bellus Health Inc.

Global Retinal Vein Occlusion Treatment Market size was valued at USD 13.92 billion in 2022 and is poised to grow from USD 15.41 billion in 2023 to USD 34.75 billion by 2031, growing at a CAGR of 10.70% during the forecast period (2024-2031).

The treatment market for retinal vein occlusion (RVO) is experiencing significant growth, attributed to the rising prevalence of RVO and the expanding elderly population susceptible to this condition. RVO, a common retinal vascular disorder, poses a risk of vision impairment and blindness if not promptly addressed. This market offers diverse treatment options, including medications, laser therapy, and surgical interventions, all aimed at enhancing blood circulation, reducing macular edema, and preventing vision loss. The market is segmented based on treatment type, end-user, and region, with anti-VEGF medications standing out as a prominent choice for controlling abnormal blood vessel growth and macular edema. The market's expansion is propelled by the increasing acceptance of advanced therapies and the growing incidence of RVO cases, particularly in North America and Europe, where well-established healthcare infrastructure and early adoption of novel treatments are evident. The Asia-Pacific region is also witnessing growth, fueled by heightened healthcare awareness and improved medical facilities. Factors such as augmented investment in research and development, advancements in diagnostic techniques, and collaborative efforts among pharmaceutical companies and research institutions are fostering the creation of innovative treatment methods. Furthermore, a rising emphasis on personalized medicine and patient-centric approaches is anticipated to propel the market forward. With the demand for effective RVO treatments on the rise, manufacturers and healthcare providers are collaborating to deliver more accessible and efficient solutions, aiming to enhance the quality of life for individuals affected by this condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Vein Occlusion Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Vein Occlusion Treatment Market Segmental Analysis

The retinal vein occlusion treatment market is segmented on the basis of disease type, treatment, end-user, and regional. Based on Disease Type the market is segmented as, Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO). Based on Treatment the market is segmented as, Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, And Others. Based on End-user the market is segmented as, Hospital & Clinics, Research and Academics, Others. Based on Regional the market is segmented as, North America, Asia Pacific, Latin America.

Drivers of the Global Retinal Vein Occlusion Treatment Market

The growth of the retinal vein occlusion market is propelled by various factors, including the increasing global prevalence of eye diseases, a rising elderly population, enhanced comprehension of eye disorders, strengthened healthcare infrastructure, technological progress, and the introduction of novel therapies. The market's momentum is further augmented by a robust pipeline and recent approvals of new drugs. With a growing number of retinal vein occlusion cases and ongoing research into treatment molecules, the effectiveness of retinal vein occlusion therapy is witnessing an upward trend. This is supported by a strong pipeline and recent drug clearances, presenting significant opportunities for the adoption of innovative retinal vein occlusion therapeutics and contributing to the market's expansion.

Restraints in the Global Retinal Vein Occlusion Treatment Market

The bioresorbable scaffolds market encounters a hurdle due to a scarcity of extensive long-term clinical data. Additional assessment is essential to conclusively determine the efficacy and safety of bioresorbable scaffold implants in comparison to traditional stents. Evaluating the outcomes will contribute to a more comprehensive understanding of their performance over an extended period.

Market Trends of the Global Retinal Vein Occlusion Treatment Market

The rising occurrence of retinal vein occlusion, especially in the elderly demographic, is fueling the need for viable treatment solutions. With the global population aging, there is a projected increase in the prevalence of this condition, which is anticipated to contribute to the expansion of the market.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Retinal Vein Occlusion Treatment Market by Disease Type

• Market Overview
• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

Global Retinal Vein Occlusion Treatment Market by Treatment

• Market Overview
• Anti-vascular Endothelial Growth Factor (Anti-VEGF)
• Corticosteroid Drugs
• and Others

Global Retinal Vein Occlusion Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Alcon
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thrombogenics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acucela Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bellus Health Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments